PharmaShots Weekly Snapshots (July 12 - 16, 2021)
Published: July 16, 2021 | Tags: Eli Lilly, Banner Alzheimer's Institute, Donanemab, P-III, TRAILBLAZER-ALZ 3 Trial, Alzheimer Disease
Published: July 16, 2021 | Tags: AcelRx, License Agreement, Aguettant, Dzuveo, EU, Pre-Filled Syringe Products, US
Published: July 16, 2021 | Tags: Bio-Thera, P-III, BAT2206, Proposed Biosimilar, Stelara, Ustekinumab
Published: July 16, 2021 | Tags: Vir, P-II, MARCH Trial, VIR-2218, VIR-3434, Functional Cure Regimen, Chronic Hepatitis B Virus Infection
Published: July 16, 2021 | Tags: Alexion, Ultomiris, ravulizumab-cwvz, P-III, Study, Generalized Myasthenia Gravis
Ipsen Signs an Exclusive WW License Agreement with IRLAB for Mesdopetam to Treat Parkinson Disease
Published: July 16, 2021 | Tags: Ipsen, License Agreement, IRLAB, Mesdopetam, Parkinson Disease
Published: July 15, 2021 | Tags: Skyhawk, Aragen, Develop, Novel Small Molecule Therapeutics
Published: July 15, 2021 | Tags: Heat Biologics, ProBioGen, Transposase System, Suspension, HEK293 Cell Line
Published: July 15, 2021 | Tags: Johnson & Johnson, Single-Shot COVID-19 Vaccine, P-I/IIa, Sub-Study, COVID 19, NEJM
Published: July 15, 2021 | Tags: Novartis, Incyte, Jakafi, ruxolitinib, P-III, REACH3 Study, Chronic Graft-Versus-Host Disease, NEJM
Galapagos Reports Results of GLPG3667 in P-Ib Study for the Treatment of Psoriasis
Published: July 15, 2021 | Tags: Galapagos, GLPG3667, P-Ib, Study, Psoriasis
Eli Lilly to Acquire Protomer Technologies for ~$1B
Published: July 15, 2021 | Tags: Eli Lilly, Acquire, Protomer Technologies, ~$1B
Published: July 14, 2021 | Tags: Caribou, First Patient Dosing, P-I, ANTLER Trial, CB-010, B- Cell Non-Hodgkin Lymphoma
Published: July 14, 2021 | Tags: Strongbridge, Post Hoc Analyses, One Year, HYPHOP Study, Keveyis, dichlorphenamide, Primary Periodic Paralysis
Published: July 14, 2021 | Tags: Astellas, License Agreement, ExCellThera, In Vitro, UM171, Pluripotent Stem Cells
Published: July 14, 2021 | Tags: Ionis, Exclusive License Agreement, Bicycle, Targeted Oligonucleotide Therapeutics, TfR1 Bicycle Technology
Hologic Receives CE Mark to Use Saliva Samples with Aptima SARS-CoV-2 Test in EU
Published: July 14, 2021 | Tags: Hologic, CE Mark, Saliva Samples, Aptima SARS-CoV-2 Test, EU
Hepion Reports Results of CRV431 in P-IIa AMBITION Trial for the Treatment of NASH
Published: July 14, 2021 | Tags: Hepion, CRV431, P-IIa, AMBITION Trial, NASH
Astellas and Affinivax Present Results of ASP3772 in P-II Study for Streptococcus Pneumoniae
Published: July 13, 2021 | Tags: Astellas, Affinivax, ASP3772, P-II, Study, Streptococcus pneumoniae
Hutchmed Reports First Commercial Sale of Orpathys (savolitinib) in China
Published: July 13, 2021 | Tags: Hutchmed, First Commercial Sale, Orpathys, savolitinib, China
Published: July 13, 2021 | Tags: Janssen, Darzalex Faspro, daratumumab, hyaluronidase-fihj, Pomalidomide, Dexamethasone, US, FDA, Approval, Multiple Myeloma
Menagen Signs a Commercialization Agreement with CKD for Biosimilar Darbepotein Alfa
Published: July 13, 2021 | Tags: Menagen, Commercialization Agreement, CKD, Biosimilar Darbepotein Alfa
Biogen Signs a License Agreement with Innocare for Orelabrutinib to Treat Multiple Sclerosis
Published: July 13, 2021 | Tags: Biogen, License Agreement, Innocare, Orelabrutinib, Multiple Sclerosis
Novo Nordisk to Acquire Prothena's ATTR Amyloidosis Program for ~$1.2B
Published: July 13, 2021 | Tags: Novo Nordisk, Acquire, Prothena, ATTR Amyloidosis Programme, $1.2B
Published: July 12, 2021 | Tags: Janssen, Stelara, ustekinumab, P-lll, UNIFI LTE Study, Active Ulcerative Colitis
Published: July 12, 2021 | Tags: Galapagos, P-III, SELECTION Trials, Filgotinib, Ulcerative Colitis, UC
Published: July 12, 2021 | Tags: Innovent, P-I, CIBI323A101 Study, IBI323, Advanced Malignant Tumors
Published: July 12, 2021 | Tags: Astellas, Seagen, Padcev, enfortumab vedotin-ejfv, US, FDA, Regular Approval, Locally Advanced, Metastatic Urothelial Cancer
Published: July 12, 2021 | Tags: Takeda, Takhzyro, lanadelumab, P-III, HELP Study, Open-Label Extension, Hereditary Angioedema Attacks, EAACI 2021
Published: July 12, 2021 | Tags: Bayer, Kerendia, finerenone, US, FDA, Approval, Chronic Kidney Disease, Type 2 Diabetes
Related Post: PharmaShots Weekly Snapshots (July 05 - 09, 2021)
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com